These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36123499)

  • 21. Pharmacokinetics and Safety of Remdesivir in Pregnant and Non-Pregnant Women with COVID-19: Results from IMPAACT 2032.
    Brooks KM; Baltrusaitis K; Clarke DF; Nachman S; Jao J; Purswani MU; Agwu A; Beneri C; Deville JG; Powis KM; Stek AM; Eke AC; Shapiro DE; Capparelli E; Greene E; George K; Yin DE; Jean-Philippe P; Chakhtoura N; Bone F; Bacon K; Johnston B; Reding C; Kersey K; Humeniuk R; Best BM; Mirochnick M; Momper JD
    J Infect Dis; 2024 Jun; ():. PubMed ID: 38839047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A combined assay for quantifying remdesivir and its metabolite, along with dexamethasone, in serum.
    Reckers A; Wu AHB; Ong CM; Gandhi M; Metcalfe J; Gerona R
    J Antimicrob Chemother; 2021 Jun; 76(7):1865-1873. PubMed ID: 33864090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetic modeling of GS-441524, the active metabolite of remdesivir, in Japanese COVID-19 patients with renal dysfunction.
    Sukeishi A; Itohara K; Yonezawa A; Sato Y; Matsumura K; Katada Y; Nakagawa T; Hamada S; Tanabe N; Imoto E; Kai S; Hirai T; Yanagita M; Ohtsuru S; Terada T; Ito I
    CPT Pharmacometrics Syst Pharmacol; 2022 Jan; 11(1):94-103. PubMed ID: 34793625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit.
    Sun D
    AAPS J; 2020 May; 22(4):77. PubMed ID: 32458279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Remdesivir-related cost-effectiveness and cost and resource use evidence in COVID-19: a systematic review.
    Murton M; Drane E; Jarrett J; Cornely OA; Soriano A
    Infection; 2023 Apr; 51(2):285-303. PubMed ID: 36224452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.
    Agostini ML; Andres EL; Sims AC; Graham RL; Sheahan TP; Lu X; Smith EC; Case JB; Feng JY; Jordan R; Ray AS; Cihlar T; Siegel D; Mackman RL; Clarke MO; Baric RS; Denison MR
    mBio; 2018 Mar; 9(2):. PubMed ID: 29511076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Remdesivir: First Approval.
    Lamb YN
    Drugs; 2020 Sep; 80(13):1355-1363. PubMed ID: 32870481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment.
    Jung LS; Gund TM; Narayan M
    Protein J; 2020 Dec; 39(6):619-630. PubMed ID: 33185784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
    Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
    mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness.
    Mechineni A; Kassab H; Manickam R
    Expert Opin Drug Saf; 2021 Nov; 20(11):1299-1307. PubMed ID: 34338121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo pharmacokinetic study of remdesivir dry powder for inhalation in hamsters.
    Sahakijpijarn S; Moon C; Warnken ZN; Maier EY; DeVore JE; Christensen DJ; Koleng JJ; Williams RO
    Int J Pharm X; 2021 Dec; 3():100073. PubMed ID: 34977555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
    de Wit E; Feldmann F; Cronin J; Jordan R; Okumura A; Thomas T; Scott D; Cihlar T; Feldmann H
    Proc Natl Acad Sci U S A; 2020 Mar; 117(12):6771-6776. PubMed ID: 32054787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature.
    Musa A; Pendi K; Hashemi A; Warbasse E; Kouyoumjian S; Yousif J; Blodget E; Stevens S; Aly B; Baron DA
    West J Emerg Med; 2020 May; 21(4):737-741. PubMed ID: 32726230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Binding of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase May Pave The Way Towards the Design of Potential Drugs for COVID-19 Treatment.
    Agoni C; Soliman MES
    Curr Pharm Biotechnol; 2021; 22(11):1520-1537. PubMed ID: 33109039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploration for the effect of renal function and renal replacement therapy on pharmacokinetics of remdesivir and GS-441524 in patients with COVID-19: A limited case series.
    Choe PG; Jeong SI; Kang CK; Yang L; Lee S; Cho JY; Han SS; Kim DK; Lee SM; Park WB; Oh MD; Kim NJ
    Clin Transl Sci; 2022 Mar; 15(3):732-740. PubMed ID: 34761554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative bioavailability study following a single dose intravenous and buccal administration of remdesivir in rabbits.
    Szente L; Renkecz T; Sirok D; Stáhl J; Hirka G; Puskás I; Sohajda T; Fenyvesi É
    Int J Pharm; 2022 May; 620():121739. PubMed ID: 35421532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2
    Gammeltoft KA; Zhou Y; Duarte Hernandez CR; Galli A; Offersgaard A; Costa R; Pham LV; Fahnøe U; Feng S; Scheel TKH; Ramirez S; Bukh J; Gottwein JM
    Antimicrob Agents Chemother; 2021 Aug; 65(9):e0268020. PubMed ID: 34097489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
    Maharaj AR; Wu H; Hornik CP; Balevic SJ; Hornik CD; Smith PB; Gonzalez D; Zimmerman KO; Benjamin DK; Cohen-Wolkowiez M;
    JAMA Pediatr; 2020 Oct; 174(10):e202422. PubMed ID: 32501511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models.
    Li Y; Cao L; Li G; Cong F; Li Y; Sun J; Luo Y; Chen G; Li G; Wang P; Xing F; Ji Y; Zhao J; Zhang Y; Guo D; Zhang X
    J Med Chem; 2022 Feb; 65(4):2785-2793. PubMed ID: 33523654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Remdesivir: A Closer Look at Its Effect in COVID-19 Pandemic.
    Taha HR; Keewan N; Slati F; Al-Sawalha NA
    Pharmacology; 2021; 106(9-10):462-468. PubMed ID: 34515227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.